[178] examined how heterogeneity and plasticity of CEA expression influence resistance to cibisatamab (CEA-TCB), a bispecific antibody targeting CEA, using patient-derived CRC organoids (PDOs). Here, CEACAM5 is linked to colorectal carcinoma.